Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

24 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 16 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 16

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 17 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 17

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 15 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 15

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 14 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 14

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 12 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 12

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 13 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 13

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 10 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 10

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 9 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 9

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 11 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 11

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 8 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 8

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 7 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 7

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Follow-Up 6 - CRFs Cabazitaxel Prostate Cancer NCT01308580 Follow-Up 6

- 13/06/17 - 1 modulo, 15 itemgroups, 76 elementi, 1 linguaggio
Itemgroups: Visit Information, Vital Signs, Tumor Assessment - Target Lesion, Tumor Assessment - Non-target lesion, Tumor Assessment - New Lesion, Bone Scan, Tumor Markers, Cancer Pain Questionnaire, Disease Status, FACT P Questionnaire, FACT P Questionnaire - Physical Well-Being, FACT P Questionnaire - Social/ Family Well-Being, FACT P Questionnaire - Emotional Well-Being, FACT P Quesionnaire - Functional Well-Being, FACT P Questionnaire - Additional Concerns
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial